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Reactive oxygen species are thought to be critical inducers of
renal inflammation and destruction. We examined the effects
of candesartan, a highly selective angiotensin II type I
receptor (AT1R) blocker, on renal inflammation and oxidative
stress. Candesartan suppressed TNF-induced chemokine
expression and NFjB activation independent of AT1R
blockade in cultured renal tubular epithelial cells. This
receptor blocker decreased reactive oxygen generation
elicited by either TNF or the pro-oxidant hydrogen peroxide
and reinstated redox homeostasis, suggesting a direct
antioxidant effect. This result was unique to candesartan
among several angiotensin II receptor blockers and occurred
in cells lacking the AT1R. A dose 5 times the standard
therapeutic dose lessened renal inflammation and
suppressed tubular NFjB activation in spontaneously
hypertensive rats. An ultrahigh dose (15 times standard)
produced an even greater beneficial effect. Angiotensin II
infusion did not cause any hemodynamic changes at either
candesartan dose denoting a complete blockade of systemic
and renal AT1R. There was, however, a dose-dependent
improvement of renal redox homeostasis. Our study suggests
that candesartan suppresses redox-sensitive NFjB-mediated
renal inflammation by a direct antioxidant effect
independent of AT1R blockade.
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Metabolism of oxygen by cells inevitably generates potentially
deleterious reactive oxygen species (ROS).1 Under normal
conditions the rate and magnitude of oxidant formation is
balanced by the rate of oxidant elimination, however, an
imbalance between pro-oxidants and antioxidants can lead to
oxidative stress and contribute to acute and chronic organ
injury.2,3 In the kidney, ROS derived from nicotinamide
adenine dinucleotide phosphate-oxidase are important cyto-
toxic and signalling mediators that play a central role in the
pathophysiology of inflammatory kidney disease, renal
dysfunction, and kidney destruction.4,5 Although ROS can
cause cell destruction by massive lipid peroxidation, in most
cases, ROS modulate signal transduction pathways by
affecting oxidation-reduction (redox)-sensitive enzymes,
organelles, and transcription factors such as nuclear factor-kB
(NF-kB).5 The tripeptide glutathione (GSH), L-g-glutamyl-L-
cysteinyl-glycine, is the most abundant antioxidant in cells
and an important determinant of redox state.6–9 Altered
redox states activate and inhibit signaling transducers in the
cytoplasm, regulate DNA binding of transcription factors in
the nucleus,7–9 and modulate the generation of diverse
proinflammatory mediators involved in the initiation
and progression of chronic renal inflammation including
cytokines, chemokines, costimulatory molecules, and
adhesion molecules.10
The renin-angiotensin aldosterone system (RAAS) and its
key component angiotensin II (AII) are potent inducers of
ROS and oxidative stress in renal11 and cardiovascular
systems.12 Blockade of the RAAS by angiotensin-convert-
ing-enzyme inhibitors and by AII type 1 receptor (AT1R)
blockers (ARBs) improves outcomes of hypertension,13
congestive heart failure,14 and chronic renal disease.15 Recent
evidence suggests that candesartan (Cand), a highly selective
ARB, has potent anti-inflammatory actions in experimental
models of cerebral ischemia16 and chronic pancreatitis,17
diseases not usually associated with activation of the RAAS.
In both human18,19 and experimental20,21 chronic kidney
disease, high-dose Cand had renoprotective effects that could
not be ascribed to altered hemodynamics. The exact
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mechanism is uncertain, however, studies suggest that Cand
regulates ROS formation in multiple tissues.16,22 The present
study examined the effects of Cand on ROS generation and
redox status in renal tubular epithelial cells, which account
for more than 95% of kidney mass and play an important
role in renal inflammation. We found that Cand suppressed
redox-sensitive NF-kB-mediated inflammation in renal
tubular cells via a direct antioxidant action that did not
depend on blockade of AT1R.
RESULTS
Cand suppresses TNF-induced expression of MCP-1 and
RANTES in tubular epithelial cells
Human proximal tubular epithelial cells (HKCs) were
exposed to tumour-necrosis factor (TNF)-a or TNF-a
combined with increasing concentrations of Cand for
different intervals. Cand suppressed TNF-induced mRNA
expression of monocyte chemoattractant protein-1 (MCP-1)
and regulated upon activation normal T-cell expressed and
presumably secreted (RANTES) in a dose- and time-
dependent manner with a maximal inhibitory effect at
105 M (Figure 1a) and lasting over 24 h (Figure 1b). A
similar pattern was observed in MCP-1 and RANTES protein
levels measured by enzyme-linked immunosorbent assay in
the conditioned media from cultured cells. At 24 h, maximal
suppression of TNF-induced MCP-1 and RANTES protein
level was observed at 105 M Cand (Figure 1c). The inhibitory
effect of Cand was evident at all time points from 12 to 48 h
(Figure 1d, e).
Cand suppression of TNF-induced chemokine expression
persists after knockdown of AT1R
Angiotensin II stimulates and AT1R blockade suppresses
chemokine production in HKC; however, because AII is not
added in our cell culture system, it seemed unlikely that Cand
blocked TNF-induced chemokine production via the AT1R.
To determine whether the AII receptor participates in the
anti-inflammatory effects of Cand, AT1R in HKCs was
knocked down by RNA interference. Near complete (480%)
suppression of AT1R protein expression was observed after
AT1R-specific RNA interference (Figure 2a, b). Nevertheless,
Cand still markedly suppressed TNF-induced mRNA (Figure 2b)
and protein (Figure 2c) expression of MCP-1 and RANTES
protein levels in silenced cells. Similar results were observed
in cells transfected with scrambled siRNA, suggesting that the
AT1R pathway is not required for inhibition of TNF-induced
MCP-1 and RANTES expression by Cand.
Cand blunts TNF-induced NF-jB activity
Expression of MCP-1 and RANTES is regulated by NF-kB. To
further understand how Cand suppresses TNF-induced
expression of MCP-1 and RANTES, we examined the effect
of Cand on NF-kB activation in HKCs with or without
silenced AT1R at multiple stages, including NF-kB transacti-
vation activity, NF-kB binding to target chemokine genes,
and phosphorylation of key components of the NF-kB
signaling pathway. Shown in Figure 3a, luciferase reporter
gene assay demonstrated that TNF-elicited luciferase activity
was significantly reduced by Cand, indicating that Cand
inhibits NF-kB transactivation activity. The inhibitory effect
of Cand was not altered after AT1R knockdown. To
determine whether Cand suppresses NF-kB activity through
regulation of nuclear protein binding to the kB cis-elements,
electrophoretic mobility shift assay was performed (Figure
3b). The nuclear extracts from HKCs bound to oligonucleo-
tide probes containing the consensus sequence for the NF-
kB-binding site and clearly displayed a gel shift band as
indicated. Supershift assay further confirmed RelA/p65 as a
major component that contributed to this binding activity. In
cells transfected with scrambled siRNA, TNF stimulation
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Figure 1 | Candesartan suppresses TNF-induced mRNA expression and protein production of MCP-1 and RANTES in a
dose- and time-dependent fashion. HKCs were treated with TNF-a (2 ng/ml), Cand (105 M), or TNF in combination with Cand in varying
concentrations (105, 107, 109 M in a, c) for 12 h (a, c) or different time intervals as indicated (b, d). After treatment, conditioned media and
mRNA were prepared and subjected to ELISA (c, d, e) or semiquantitative (a) and real-time (b) RT-PCR. In (b) and (d, e), *Po0.05 vs TNF
alone treated cells at each time point; in (c), *Po0.05 vs all other groups (n¼ 5).
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resulted in an enhanced binding, which was obliterated by
Cand. This inhibitory effect of Cand was entirely preserved
after AT1R knockdown (Figure 3b). To explore whether Cand
regulation of NF-kB to DNA-binding activity functions on
the target gene level, chromatin immunoprecipitation assay
was carried out and quantified by densitometry (Figure 3c).
In cells transfected with scrambled siRNA, promoter frag-
ments of the MCP-1 and RANTES genes coprecipitated with
RelA/p65 following TNF stimulation, demonstrating that
TNF induces NF-kB binding to these genes. Cand suppressed
this physical association, and this was not altered by AT1R
silencing. Next, whether Cand altered phosphorylation of key
components of the NF-kB pathway was examined by im-
munoblot followed by densitometric analysis (Figure 3d).
IkBa and RelA/p65 were both phosphorylated following TNF
stimulation, which led to a reduction in the abundance of
IkBa due to phosphorylation triggered proteasome-mediated
degradation. Cand treatment blocked all of these changes in
HKCs, in both AT1R-silenced or scrambled cells. These
findings suggest that Cand intercepts TNF-induced NF-kB
activation and that AT1R is not required.
ROS is essential and sufficient for TNF-induced activation
of redox-sensitive NF-jB
A growing body of evidence suggests that ROS regulate the
activity of numerous redox-sensitive transcription factors
including NF-kB.23 To examine the role of ROS in TNF-
induced NF-kB activation and downstream expression of
chemokines, ROS levels and GSH redox status were measured
in HKC. Probed by the ROS marker, dichlorofluorescein
(DCF), TNF elicited an immediate ROS burst (Figure 4a),
similar to the effect of the pro-oxidant hydrogen peroxide
(Figure 4b). Pyrrolidine dithiocarbamate (PDTC), a specific
ROS scavenger, almost entirely eliminated TNF-induced
production of ROS (Figure 4b). TNF-induced ROS genera-
tion was associated with marked reductions in GSH level and
the GSH/glutathione disulfide ratio, which could be mi-
micked by hydrogen peroxide and prevented by PDTC
(Figure 4c). TNF-induced phosphorylation of RelA/p65 and
IkBa and degradation of IkBa was also mimicked by
hydrogen peroxide and prevented by PDTC (Figure 4d). A
similar pattern was observed in the regulation of expression
of NF-kB target chemokine genes MCP-1 and RANTES
(Figure 4e). Overall, these findings suggest that ROS mediates
TNF-induced activation of redox-sensitive NF-kB and
expression of NF-kB-dependent chemokines.
Cand is a potent antioxidant that normalizes cellular redox
status
Recent studies in animals suggest that Cand decreases ROS
formation.17 To understand how Cand regulates redox state,
HKC were loaded with DCF and stimulated with TNF, which
generated abundant ROS indicated by the DCF green
fluorescence (Figure 5a). DCF fluorescence was significantly
attenuated in cells cotreated with Cand (Figure 5a). ROS
levels were also quantified by fluorometry analysis, which
confirmed that Cand suppressed ROS formation in a dose-
(Figure 5b) and time (Figure 5c)-dependent manner. The
effect of Cand was similar to that of PDTC or N-
acetylcysteine (Figure 5b), two specific ROS scavengers. Cand
also attenuates hydrogen peroxide-induced ROS activity in a
dose-dependent manner, consistent with a direct antioxidant
effect (Figure 5b). In parallel with the changes in ROS
activity, Cand also regulated cellular redox status. GSH levels
(Figure 5d) and the reduced/oxidized glutathione (GSH/
glutathione disulfide) ratio (Figure 5e) were decreased by
TNF and Cand abrogated this effect, reminiscent of the
action of PDTC or N-acetylcysteine. To verify our DCF
fluorometry data, cells were labeled with another sensitive
ROS indicator dihydrorhodamine and ROS levels determined
by flow cytometry (Figure 5f). Cand obviously attenuated
TNF-induced right shift of the fluorescence peak in a dose-
related pattern. These data suggest that Cand is a powerful
antioxidant.
The antioxidant effect is unique to Cand and independent
of AT1R blockade
To explore whether the antioxidant effect of Cand is
attributable to AT1R blockade, AT1R was selectively silenced.
In cells transfected with the scrambled siRNA, Cand
significantly attenuated TNF-induced ROS generation and
restored the GSH level and GSH/glutathione disulfide ratio.
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Figure 2 | Candesartan AT1R antagonizing activity is not
required for its suppressive effect on TNF-induced MCP-1 and
RANTES expression. HKCs were transfected with AT1R-specific or
scrambled siRNA followed by different treatments as indicated in
Figure 1 for 12 h (b) or 24 h (c). (a) Immunocytochemistry
demonstrated that AT1R expression (white arrow heads) was not
affected in cells transfected with scrambled siRNA, but largely
silenced by AT1R-specific siRNA; (b) Immunoblot analysis showed
that AT1R abundance was reduced after RNAi, whereas the
suppressive effect of Cand (105 M) on mRNA expression of MCP-1
and RANTES was not affected. (c) The suppressive effect of Cand
(105 M) on protein production of MCP-1 and RANTES was not
affected after AT1R knockdown. *Po0.05, #Po0.05 vs TNF alone
treated cells transfected with the same siRNA (n¼ 6).
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This effect was largely preserved after AT1R silencing (Figure
6a). To rule out the possibility that incomplete AT1R
knockdown contributed to the beneficial effect of Cand, a
line of Swiss R3T3 cells, which lacks the AT1R,24 was studied.
Shown in Figure 6b, TNF-induced ROS generation in R3T3
cells, as measured by DCF fluorometry, was markedly
diminished by Cand with a typical dose–response pattern,
demonstrating that AT1R are not required for its antioxidant
action. Furthermore, to examine whether this antioxidant
action is specific for Cand, the effects of two other ARBs,
irbesartan and losartan, were compared to Cand (Figure 6c).
In contrast to the dose-dependent suppression of TNF-
induced ROS formation by Cand, irbesartan or losartan at
the same concentrations (105, 107, 109 M) had minimal
effect, suggesting that the antioxidant action is not a class
effect shared by all ARBs, but rather is specific to Cand.
Recent studies suggest that some ARBs, such as telmisartan,25
activate the peroxisome proliferator-activated receptor-g
(PPARg), another effect that is independent of AT1R
blockade. However, only very weak, if any, PPARg agonist
activity was reported for Cand.25 Furthermore, GW9662, a
selective PPARg antagonist, failed to block Cand’s inhibitory
effect on ROS generation in this system (Figure 6c),
demonstrating that Cand’s antioxidant action is not
mediated by PPARg.
Cand normalizes redox status and suppresses NF-jB
activation and inflammation in experimental chronic
kidney disease
Whether Cand also acts as an antioxidant for the kidney
in vivo was next examined. Studies were conducted in
spontaneously hypertensive rats (SHR) treated with vehicle,
high or ultrahigh dose Cand. High and ultrahigh dose Cand
exhibited equal effects on controlling whole body weight
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Figure 3 | Candesartan obliterates TNF-elicited NF-jB activity independently of AT1R blockade. (a) HKCs were co-transfected with
siRNA or the 3 kB luciferase reporter gene construct followed by different treatments as indicated in Figure 2 for 12 h. Cells were
collected and cell lysates processed for luciferase assay. *Po0.05 vs other groups transfected with the same siRNA (n¼ 6). (b) After different
treatments, nuclear extracts were prepared from RNA silenced cells or control cells followed by EMSA by using oligonucleotide probes
containing the consensus sequence for the NF-kB-binding site. For supershift assay, anti-p65 antibody or control preimmune
immunoglobulin (Ig) was applied. (c) After RNAi, cells were treated as indicated for 3 h and then prepared for chromatin
immunoprecipitation (ChIP) assay using anti-RelA/p65 antibody. The amount of MCP-1 and RANTES DNA that coprecipitated with
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(Figure 7a), normalizing systemic hypertension (Figure 7b),
attenuating proteinuria (Figure 7c), and improving kidney
dysfunction (Figure 7d). Cand suppressed renal injury and
inflammation in both groups of SHR (Figure 7f and g),
assessed by the number of ED-1-positive infiltrating inflam-
matory cells (Figure 7e–g, k); however, suppression of
inflammation was significantly greater in the ultrahigh dose
group (Figure 7g). A similar pattern was noted in tubular
NF-kB activation examined by immunohistochemistry
(Figure 7h–j) and by immunoblot analysis (Figure 7l) of
phosphorylated p65, with the greatest suppression in the
ultrahigh dose group. Renal expression of NF-kB-dependent
chemokines, including MCP-1 and RANTES, were also
diminished by Cand with the greatest effect in the ultrahigh
dose group (Figure 7m). One possibility is that the superior
anti-inflammatory and renoprotective actions of ultrahigh
dose Cand result from increased binding of AII to the AII
type 2 receptor (AT2R). However, AT2R expression in the
diseased kidney was not altered after Cand treatment (Figure
7n). Another possibility is that AT1R blockade was
incomplete at the lower dose of Cand. An exogenous AII
challenge test was performed in animals from each group to
examine this issue. Infusion of exogenous AII fails to induce
any change in systemic or renal hemodynamics, including
mean arterial pressure (Figure 8a), renal plasma flow (Figure
8b), and glomerular filtration rate as assessed by inulin
clearance (Figure 8c) in SHR on both high and ultrahigh dose
of Cand, demonstrating that AT1R are totally blocked in both
groups. Therefore, any residual differences between the two
groups should be independent of AT1R. Consistent with our
in vitro findings, Cand raised GSH level (Figure 8d) and the
GSH/glutathione disulfide ratio (Figure 8e) in a dose-
dependent fashion, demonstrating that Cand also improves
redox homeostasis in the diseased kidney. Regression analysis
demonstrated that GSH redox status was inversely correlated
with the magnitude of NF-kB activation (Figure 8f) and the
number of inflammatory cells (Figure 8g) in the diseased
kidney. Of note, results in the high and ultrahigh dose groups
were well segregated with regard to the reciprocal correlation
between GSH redox status and both the magnitude of redox-
sensitive NF-kB activation and the extent of inflammation in
the kidney, strongly suggesting that regulation of redox status
is a major determinant of Cand’s renoprotective effects.
DISCUSSION
Renal inflammation is an important pathway, common to
diverse chronic kidney diseases, preluding renal fibrosis and
driving progression to end-stage renal failure.26,27 Epidemio-
logic data suggest that inflammation is one of the potentially
modifiable risk factors in most forms of chronic kidney
disease.28 Despite extensive investigation, the exact mechan-
isms responsible for the initiation and progression of chronic
renal inflammation remain controversial. Oxidative stress is
one factor for which considerable evidence exists.29 Oxidative
stress has been associated with the aging process and many
chronic diseases,8,30 including chronic kidney disease.29
Pharmacological reduction of oxidant stress has been
proposed and to some extent shown to reduce renal
inflammation and injury.31 In the present study, we report
that at high doses, Cand possesses significant antioxidant
properties that suppress chronic renal inflammation and that
this is independent of AT1R blockade.
The beneficial effects of ARBs such as Cand on renal and
cardiovascular inflammation and injury have been exten-
sively studied and our results are largely consistent with these
studies. Cand suppresses ROS formation, improves redox
status, and reduces inflammation in a variety of experimental
disease models in multiple organ systems including the
liver,32 heart,33 and kidney.20 However, in those studies,
Cand’s antioxidative effect was attributed to blockade of
AT1R and inhibition of AII-induced generation of ROS and
oxidative stress, whereas our data suggest that AT1R are not
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Figure 4 | ROS are essential and sufficient for activation of
NF-jB and induced expression of its target genes. (a) HKCs
were labeled with DCF (green) and stimulated with TNF (2 ng/ml)
for varying intervals followed by fluorometric analysis. Results
were determined by fluorometry and presented as percent
change of light units from baseline as folds of normal controls
(n¼ 6). (b) HKCs were labeled with DCF and treated with TNF
(2 ng/ml), an ROS scavenger pyrrolidine dithiocarbamate (PDTC,
7.5mM), hydrogen peroxide 100mM or in combination for 15 min
followed by fluorometric analysis. #Po0.05 vs nontreated cells;
*Po0.05 vs TNF alone treated cells (n¼ 6). (c) HKCs received
various treatments for 15 min followed by GSH and GSSG assay.
#Po0.05 vs nontreated cells; *Po0.05 vs TNF alone treated cells
(n¼ 6). (d) HKCs were treated for 1 h followed by immunoblot
analysis of the cell lysates for different molecules. (e) HKCs were
treated for 12 h followed by mRNA extraction and profiling of
MCP-1 and RANTES expression by real-time RT-PCR. #Po0.05 vs
nontreated cells; *Po0.05 vs TNF alone treated cells (n¼ 6).
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involved. Consistent with this view, components of the RAAS
are felt to play little role in animals with ischemic cerebral
injury16 and in pancreatic b-cell injury in diabetic db/db
mice.34 Nevertheless, Cand significantly reduced ROS for-
mation and protected from injury in these models, suggesting
that an AII independent mechanism might be responsible. To
further examine whether AII blockade plays a role in the
protective effect of Cand on redox homeostasis, we utilized
renal tubular epithelial cells in culture, an in vitro model
stimulated with TNF, a prototype of proinflammatory
mediators, instead of components of the RAAS. Cand
markedly suppressed TNF-induced chemokine production.
To verify that the effects of Cand were not dependent on
blocking the RAAS, the AT1R was silenced in the cultured
cells and results confirmed in R3T3 cells that lack AT1R.
Nevertheless, Cand still ameliorated all proinflammatory
responses, providing further evidence that its anti-inflam-
matory effect did not depend on blockade of AII/AT1R
signaling axis.
Many proinflammatory mediators, including chemokines
MCP-1 and RANTES, are under the tight control of
transcription factor NF-kB.35 Activity of NF-kB is regulated
by a variety of factors and signaling pathways. We found that
redox-dependent regulation of NF-kB also mediates TNF’s
proinflammatory effects in renal tubular cells. The mechan-
ism by which ROS regulate NF-kB activity is still uncertain.36
Tyrosine kinase activity, which regulates phosphorylation and
activation of various components of the NF-kB pathway, is
stimulated by oxidants and decreased by antioxidants.37
Tyrosine phosphatase activity, which dephosphorylates the
protein tyrosine residues in the NF-kB signaling molecules
that are phosphorylated by tyrosine kinase, is suppressed by
oxidants and sustained by antioxidants.37,38 Cand effectively
blocks TNF or hydrogen peroxide-dependent release of ROS
in tubular epithelial cells and restores redox homeostasis, and
this may account for its effects on NF-kB RelA/p65
phosphorylation as well. Furthermore, this antioxidant
property was not common to all ARBs, but was specific to
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107, 109 M) for 15 min (b, d, e) or the indicated time (c) followed by fluorometric analysis (b, c) or GSH and GSSG assay (d, e).
In (b, d, e) *Po0.05 vs TNF other groups treated with TNF; #Po0.05 vs other groups treated with hydrogen peroxide (n¼ 6).
In (c) *Po0.05 vs TNF alone treated cells (n¼ 6). (f) HKCs were treated with TNF (2 ng/ml) or Cand at indicated concentrations for 15 min
and then labeled with dihydrorhodamine. Final ROS levels were determined by flow cytometry.
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Cand. Cand has a very weak PPARg agonizing activity25 and
PPARg was not required for the antioxidant action.
Whether Cand possesses intrinsic antioxidant activity in
the kidney in vivo is difficult to investigate because of the
drug’s well-known effects on AII-induced ROS generation.
The fact that at least some of the protective effects of Cand
appear to be independent of hemodynamic changes is
consistent with the hypothesis that AT1R blockade may not
be central to all of these actions. An ideal model to test this
hypothesis would be one with no AT1R; for example, an
AT1R knockout mouse. However, mice express two types of
AT1R, AT1aR and AT1bR, and double knockout of the two
receptors is lethal.39 Mice with only the AT1aR knockout
survive, however, AII still functions via AT1bR, and Cand
blockade of AT1bR would still occur. In this context,
exhaustive supramaximal blockade of AT1R provides a
practically and highly efficient way to effectively silence the
signaling of this key receptor. To this end, SHR were given
high and ultrahigh doses of Cand to discern AT1R-
independent effects in vivo. Hemodynamic data suggested
that AT1R were completely blocked in animals from both
groups, as evidenced by a total lack of an effect of exogenous
AII on either systemic or renal hemodynamics. Nevertheless,
tubular NF-kB activation, renal inflammation, and injury
were suppressed to a much greater degree in ultrahigh dose as
compared to the high-dose group. This finding is consistent
with two recent clinical trials21,22 in chronic renal disease, in
which higher than usual doses of Cand produced superior
renal protection, as evidenced by greater reductions in
proteinuria. Our data are also consistent with the study of
Yamada et al.,17 who reported that Cand attenuated
inflammation and injury in a rat model of pancreatitis. In
addition to AT1R, recent data also implicate AT2R in the
modulation of renal inflammation and injury.40,41 However,
the exact role of AT2R remains highly controversial. Some
studies demonstrate that AII-mediated NF-kB activation also
occurs via AT2R and that selective blockade of AT2R could
attenuate renal injury in animal models with progressive
chronic kidney disease, consistent with a detrimental role of
AT2R in renal disease.40,41 In contrast, progression of kidney
disease and injury was accelerated in AT2R knockout mice
with experimental obstructive nephropathy,42 whereas over-
expression of AT2R remarkably ameliorated remnant kidney
disease in mice,43 suggesting that AT2R exert a protective
effect. As has been previously reported,44 we found that AT2R
expression was elevated in diseased kidney; but barely
affected by Cand treatment, indicating that the additional
renoprotecive effect by ultrahigh dose Cand may not depend
on AT2R. As an alternative, we examined the effects of Cand
on GSH redox status in the kidney. Consistent with our in
vitro findings, Cand corrected redox imbalance in SHR
kidneys in a dose-dependent fashion, with the greatest effect
in the ultrahigh dose group. This suggests that Cand
suppresses chronic renal inflammation, at least in part, via
a direct antioxidant effect.
In summary, the selective AT1R blocker, candesartan,
functions as an antioxidant, suppressing ROS formation,
restoring redox homeostasis, intercepting NF-kB activation
and chemokine production, and ameliorating renal inflam-
mation and injury. Higher doses of candesartan might have
additional beneficial effects as compared to conventional
doses in preventing progression of chronic renal disease by
reducing oxidative stress.
MATERIALS and METHODS
Cell culture
Human proximal tubular epithelial cells were grown in
Dulbecco’s modified Eagle’s medium/F12 that contained 5%
fetal bovine serum. Swiss R3T3 cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum. All cells underwent serum starvation
for 24 h before treatment. TNF-a (R&D Systems,
Minneapolis, MN, USA) and Cand (AstraZeneca, Boston,
MA, USA) were added to the culture with fresh serum-free
medium at indicated concentrations. Cell viability was
assessed by Trypan blue exclusion and was over 95% in all
experiments.
RNA extraction and reverse transcription-PCR
Total RNA was extracted and the first-strand cDNA was
prepared.45 Semiquantitative RT-PCR of MCP-1, RANTES,
and GAPDH was carried out as previously described.46 PCR
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products resolved in agarose gels were photographed under
ultraviolet light. Alternatively, quantitative real-time PCR was
conducted on a Stratagene M 4000 multiplex quantitative
PCR system (Stratagene, La Jolla, CA, USA) using primers
specific for human MCP-1, RANTES, rat AT2R,44 and
GAPDH. The transcript level of each specific gene was
normalized to GAPDH amplification.
ELISA of chemokines
The contents of MCP-1 and RANTES in conditioned
media or kidney homogenates were determined by
specific Quantikine sandwich enzyme-linked immunosor-
bent assay kits for human MCP-1 and RANTES (R&D
Systems). Results were normalized for cell numbers or
protein levels.
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RNA interference
AT1R-specific siRNA sequence (50-GGAGAAAAUGCAUUA
UGUGtt-30) was designed according to the complete coding
sequence of human AT1R gene (GenBank accession no.
009585). In addition, a scrambled sequence (50-AATGT
ACTCACTACGAGTGCG-30) was designed as control for
RNA interference. Efficiency of lipofectamine (Invitrogen,
Carlsbad, CA, USA)-mediated gene-silencing efficiency was
assessed by immunocytochemistry staining or immunoblot
analysis for AT1R. Near complete (480%) suppression of
AT1R protein expression was observed in cells transfected
with AT1R-specific siRNA.
Luciferase reporter gene assay
The reporter construct pGL-3kB-Luc, a firefly luciferase
reporter gene driven by three copies of an NF-kB consensus
sequence,47 was transfected to HKCs using Lipofectamine. A
fixed amount of internal control reporter Renilla reniformis
luciferase driven under thymidine kinase promoter (pRL-TK;
Promega, Madison, WI, USA) was co-transfected to normal-
ize transfection efficiency. Luciferase activity was determined
using the Dual-Glo luciferase assay kit (Promega). The
relative NF-kB transactivation activity was expressed as the
fold change of firefly luciferase activity after normalization
for R. reniformis luciferase activity.
Fluorescent immunocytochemistry
Cells were fixed with 4% paraformaldehyde.48 Following
donkey serum blocking for 30 min, cells were incubated with
the specific primary antibody to AT1R (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and then the Alexa
fluorophore 488-conjugated secondary antibody (Invitro-
gen). Finally, cells were stained with propidium iodide and
mounted with Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA) and visualized using a
fluorescence microscope.
Nuclear extract preparation and electrophoretic mobility
shift assay
Nuclear extracts were prepared from HKCs after different
treatments using the NE-PER extraction kit (Pierce, Rock-
ford, IL, USA). Samples with equal amounts of total protein
were processed for electrophoretic mobility shift assay as
described before46 by using LightShift EMSA kits (Pierce).
NF-kB consensus double-stranded oligonucleotides (50-
agttgaggggactttcccaggc-30) were labeled and used as probes.
For supershift assay, the binding reaction was carried out in
the presence of an anti-p65 antibody or a preimmune IgG
(Santa Cruz Biotechnology).
Detection of ROS generation by fluorescence
The oxidation of 50,60-chloromethyl-20,70-dichlorodihydro-
fluorescein diacetate-acetyl ester (Molecular Probes, Eugene,
OR, USA) was used to assess intracellular ROS. Cleavage of
the ester groups by intracellular esterases and oxidation by
ROS generates intracellular fluorescent DCF derivatives.
Briefly, cells were loaded with 20 mM 50,60-chloromethyl-
20,70-dichlorodihydrofluorescein diacetate-acetyl ester and
incubated for 0.5 h. Then, fresh serum-free media was added,
and a baseline fluorescence reading was measured before
treatment. Fluorescence was determined at different time
points following treatments.
Microscopic detection of ROS-generated fluorescence
Cells were treated as indicated and then loaded with 1.0 mM
50,60-chloromethyl-20,70-dichlorodihydrofluorescein diacetate-
acetyl ester at 37 1C for 0.5 h. After phosphate-buffered saline
wash, cells were fixed in a 3.7% formaldehyde solution,
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counterstained with propidium iodide, and visualized with a
fluorescence microscope.
Detection of ROS by flow cytometry
After indicated treatments, cells were washed with phos-
phate-buffered saline and trypsinized, followed by incubation
with 0.5 mM dihydrorhodamine 123 (Sigma) for 30 min at
37 1C. The ROS was determined by the fluorescent intensity
by flow cytometry with excitation at 490 nm and emission at
520 nm.
Measurement of intracellular levels of reduced and
oxidized glutathione
Tripeptide glutathione (GSH) and glutathione disulfide levels
in cell lysates or kidney homogenates were determined
spectrophotometrically as described before.49 Results were
normalized by total protein contents.
Design of the animal experiment
Male SHR underwent unilateral nephrectomy at 8 weeks old
to accelerate the kidney disease. Rats were randomly assigned
to one of three groups and received treatments 3 days after
surgery. Vehicle-treated group, rats received vehicle treatment
(vehicle; n¼ 13); high-dose group (n¼ 13); and ultrahigh-
dose group (n¼ 13), rats received 25 mg/kg per day Cand
(five times of regular dose) and 75 mg/kg per day Cand,
respectively, added to the drinking water. Rats were otherwise
housed in the standard fashion and treatment was continued
for 14 months to explore the long-term effect of high-dose
Cand. Three untreated normal Wistar-Kyoto rats were
included as an additional control.
Exogenous AII challenge test
The completeness of AT1R blockade was assessed 2 week after
initiation of Cand therapy in three SHR rats from each
group. Mean arterial pressure was monitored, glomerular
filtration rate was determined by inulin clearance,45 and renal
plasma flow was measured by ultrasonic flow probe.50 After
two 15-min baseline periods, rats received an intravenous
infusion of AII at a rate of 0.2 mg/kg per min. After a 15 min
equilibration period, mean arterial pressure, glomerular
filtration rate, and renal plasma flow were again determined
during two additional 15 min periods.
Immunohistochemistry staining and morphologic analysis
Formalin-fixed paraffin embedded kidneys were prepared in
3-mm-thick sections. Immunohistochemical staining was
performed as described before.51 The antibodies for ED-1
were purchased from Serotec (Oxford, UK) and the antibodies
for phosphorylated NF-kB p65 from Cell Signaling Technol-
ogy (Beverly, MA, USA). As a negative control, the primary
antibody was replaced by nonimmune serum from the same
species; no staining occurred. Severity of inflammation was
graded by absolute counting of ED-1-positive cells in each field
and reported as the mean number of cells per square meter in
20 random fields per rat in 10 rats per group.
Western immunoblot analyses
Human proximal tubular epithelial cells were lysed and rat
kidneys homogenized in RIPA buffer supplemented with
protease inhibitors. Samples with equal amounts of total
protein (50 mg/ml) were processed for immunoblot as
described previously.51 The antibodies against p-RelA/p65,
p-IkBa, RelA/p65, IkBa, and actin were purchased from Cell
Signaling Technology.
Chromatin immunoprecipitation assay
The in situ interaction between NF-kB and promoters of
chemokines in HKCs was examined by chromatin immuno-
precipitation assay as described before42 by using a
commercially available kit (Upstate Biotechnology, Charlottes-
ville, VA, USA) according to the manufacturer’s instructions.
Statistical analyses
All data are expressed as mean±s.d. Unless otherwise
indicated, all experimental observations were repeated six
times. Statistical analysis of the data from multiple groups
was performed by analysis of variance followed by Student–-
Newman–Keuls tests. Data from two groups were compared
by Student’s-t test. Linear regression analysis was applied to
examine possible relationships between two parameters.
Po0.05 was considered significant.
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